DongKoo Bio & Pharma Co. Ltd. (006620) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DongKoo Bio & Pharma Co. Ltd. (006620) has a cash flow conversion efficiency ratio of 0.031x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩4.46 Billion ≈ $3.02 Million USD) by net assets (₩142.58 Billion ≈ $96.62 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is DongKoo Bio & Pharma Co. Ltd. worth for the company's overall valuation and market capitalisation.
DongKoo Bio & Pharma Co. Ltd. - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how DongKoo Bio & Pharma Co. Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
DongKoo Bio & Pharma Co. Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DongKoo Bio & Pharma Co. Ltd. ranked by their cash flow conversion efficiency. Explore DongKoo Bio & Pharma Co. Ltd. earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
CESSATECH A/S DK -20
F:8GN
|
-0.361x |
|
Is Girisim Sermayesi Yatirim Ortakligi AS
IS:ISGSY
|
-0.007x |
|
Gryphon Digital Mining Inc.
NASDAQ:GRYP
|
0.080x |
|
Fold Holdings, Inc. Class A Common Stock
NASDAQ:FLD
|
-0.181x |
|
Rig Tenders Tbk
JK:RIGS
|
0.052x |
|
Nissan
TA:NISA
|
0.039x |
|
Microba Life Sciences Ltd
AU:MAP
|
-0.184x |
|
Honey Badger Silver Inc
V:TUF
|
-0.508x |
Annual Cash Flow Conversion Efficiency for DongKoo Bio & Pharma Co. Ltd. (2015–2025)
The table below shows the annual cash flow conversion efficiency of DongKoo Bio & Pharma Co. Ltd. from 2015 to 2025. View DongKoo Bio & Pharma Co. Ltd. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩152.16 Billion ≈ $103.12 Million |
₩-4.29 Billion ≈ $-2.91 Million |
-0.028x | -117.11% |
| 2024-12-31 | ₩105.33 Billion ≈ $71.38 Million |
₩17.34 Billion ≈ $11.75 Million |
0.165x | +407.23% |
| 2023-12-31 | ₩110.44 Billion ≈ $74.85 Million |
₩3.59 Billion ≈ $2.43 Million |
0.032x | -80.29% |
| 2022-12-31 | ₩102.11 Billion ≈ $69.20 Million |
₩16.82 Billion ≈ $11.40 Million |
0.165x | -7.88% |
| 2021-12-31 | ₩100.12 Billion ≈ $67.85 Million |
₩17.90 Billion ≈ $12.13 Million |
0.179x | +126.00% |
| 2020-12-31 | ₩94.65 Billion ≈ $64.14 Million |
₩7.49 Billion ≈ $5.08 Million |
0.079x | -33.16% |
| 2019-12-31 | ₩85.65 Billion ≈ $58.05 Million |
₩10.14 Billion ≈ $6.87 Million |
0.118x | +1178.70% |
| 2018-12-31 | ₩72.10 Billion ≈ $48.86 Million |
₩-791.20 Million ≈ $-536.19K |
-0.011x | -104.36% |
| 2017-12-31 | ₩37.74 Billion ≈ $25.58 Million |
₩9.51 Billion ≈ $6.44 Million |
0.252x | -55.89% |
| 2016-12-31 | ₩22.05 Billion ≈ $14.94 Million |
₩12.59 Billion ≈ $8.53 Million |
0.571x | -79.00% |
| 2015-12-31 | ₩2.55 Billion ≈ $1.73 Million |
₩6.93 Billion ≈ $4.70 Million |
2.719x | -- |
About DongKoo Bio & Pharma Co. Ltd.
DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral,… Read more